– IRELAND, Dublin – Ovoca Bio plc (LON: OVB; ISE: OVXA) a biopharmaceutical company with a focus on women’s health, today announced the appointment of Dr. Kristina Zakurdaeva (MD, Ph.D.) to its Board as an Independent Non-Executive Director effective immediately, succeeding Chris Wiltshire who has resigned from the Board and his role of Chief Business Officer with immediate effect.
“We are extremely excited to appoint Kristina Zakurdaeva to our Board. Her appointment, following that of Anastasia Levashova, adds to the complementary skill sets and breadth of perspectives on the Board of Ovoca Bio. Dr. Zakurdaeva brings extensive expertise in biotech and drug development in the USA and globally. Her strong clinical and scientific background, as well as business development experience, will be invaluable in the next stages of Ovoca Bio’s journey.” said CEO and interim Chairman, Kirill Golovanov.
About Dr. Kristina Zakurdaeva
Dr. Zakurdaeva currently serves as CEO of New York-based Incuron, a drug development company in the oncology sector. Before Incuron, she served as CMO at Gero (Singapore/Russia), a drug discovery company focused on aging and aging-related diseases, where she developed a clinical strategy for the company’s pipeline.
Before Incuron, Kristina worked as a Scientific Advisor at Bristol-Myers Squibb and later headed oncology and immunology R&D projects in the Biomed Cluster of the Skolkovo Foundation (Moscow) where she successfully launched the Cancer Center of Excellence. Dr. Zakurdaeva is a Founder and Chair of the Foundation Board for the Foundation for Cancer Research Support (Russia) and has authored numerous, recent, peer-reviewed publications and co-authored a scientific discovery in genetics. Kristina holds a medical doctor’s degree in internal medicine and hematology, as well as a Ph.D. in the genetics of acute leukemia.
About Ovoca Bio
Ovoca Bio is a European-based biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder.
The Company’s lead product, BP-101, a novel synthetic peptide administered through a nasal spray, is clinically validated, with Phase II and Phase III studies conducted in Russia demonstrating statistically significant improvement in several key efficacy outcomes, including an increase in female sexual desire and reduction of symptoms of distress associated with HSDD.
Ovoca Bio is seeking to develop the drug for major global markets – in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation.
For more information: https://ovocabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.